Halo Labs Analysis: $13M Raised
What is Halo Labs?
Halo Labs specializes in particle analysis technology for biotherapeutic development. Their innovative approaches, including Backgrounded Membrane Imaging and Fluorescence Membrane Microscopy, enhance the accuracy and speed of particle identification. This technology accelerates decision-making in drug development and manufacturing processes, ensuring safety and quality in biotherapeutics.
Employees
11-50
Industry
Biotech, HealthTech, Data Analytics
Product Features & Capabilities
- Aura particle analyzers for various therapeutic workflows
- Backgrounded Membrane Imaging technology for comprehensive particle analysis
- Fluorescence Membrane Microscopy for particle identification
- Aura PTx for protein and antibody therapeutics
- Aura GT for gene therapy workflows.
Use Cases
Analyze particle contamination in biotherapeutics; Conduct lot release testing for quality control; Assess protein stability and formulation development; Screen viral vector candidates in gene therapy; Ensure cell viability in cell therapy applications.
How much Halo Labs raised
Series C - $6 million
July 11, 2022Lead Investor: Agilent Technologies Inc., Research Corporation Technologies, Broad Oak Capital Partners, BioAdvance
Round - $7 million
December 29, 2022Other Considerations
Recently acquired by Waters Corporation; Focused on compliance with USP 788 standards; Offers innovative solutions for early-stage biotherapeutic development.
See something that needs updating? Suggest edits to this profile.
